



## Shattuck Labs Announces Participation in Upcoming September Conferences

September 1, 2021

AUSTIN, TX and DURHAM, NC, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: [STTK](#)), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in three virtual investor conferences in September 2021.

### Presentation Details

Conference: Citi 16th Annual BioPharma Virtual Conference  
Format: Panel Discussion, "Framing the Tip of the Spear for Novel Antibodies and Protein Therapeutics"  
Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer  
Date: September 9, 2021  
Time: 1:25 p.m. EST

Conference: H.C. Wainwright 23rd Annual Global Investment Conference  
Format: Corporate Presentation  
Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer  
Date: September 13, 2021  
Time: 7:00 a.m. EST

Conference: Morgan Stanley 19th Annual Global Healthcare Conference  
Format: Fireside Chat  
Presenters: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer and Andrew Neill, M.B.A., Shattuck's Chief Financial Officer  
Date: September 15, 2021  
Time: 11:45 a.m. EST

A live webcast of the panel discussion, corporate presentation, and fireside chat will be available on the [Events & Presentations](#) section of the Company's website. A replay of the webcasts will be archived for up to 90 days following the presentation date.

### About Shattuck Labs, Inc.

Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC<sup>®</sup>, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRP $\alpha$ -Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN<sup>™</sup>, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: [www.ShattuckLabs.com](http://www.ShattuckLabs.com).

### Investor Contact:

Conor Richardson  
Senior Director, Finance & Investor Relations  
Shattuck Labs, Inc.  
[InvestorRelations@shattucklabs.com](mailto:InvestorRelations@shattucklabs.com)

### Media Contact:

Stephanie Ascher  
Managing Director  
Stern Investor Relations, Inc.  
[Stephanie.ascher@sternir.com](mailto:Stephanie.ascher@sternir.com)



Source: Shattuck Labs, Inc.